monopoly
Teva settles ‘pay-to-delay’ case with FTC
February 21, 2019Business Services, Sales and Marketing FTC, Teva, antitrust, drugs, generics, monopoly
Teva Pharmaceuticals has settled a dispute with the Federal Trade Commission (FTC) over three separate federal court antitrust lawsuits involving …
Latest content
The evidence bar impacting UK medical cannabis access
November 6, 2026
Addressing the rheumatic disease diagnostic gap in primary care
November 5, 2026
